Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Goes In Big On New Valentine Nektar

Executive Summary

Bristol paid a handsome $1.85bn upfront for access to Nektar's lead immuno-oncology program NKTR-214 to study in combination with its own drugs, but the expense was viewed by some as a smart play versus buying Nektar outright.

Advertisement

Related Content

A Plea For Patience: Bristol/Nektar's Opdivo/NKTR-214 Combo Responses Deepen Over Time
Scrip's Rough Guide To IL-2: Mother Of All Cytokines
Nektar's NKTR-214 IO Deal With Bristol Looks Even Sweeter With More Data
Late-Stage CNS Drugs Key For Alkermes, But Early-Stage IL-2 Agonist Fascinates
Bristol Debuts Opdivo/Yervoy Data In New First-Line Lung Cancer Bid
Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy
Nektar's IL-2 Impresses In Combination With Bristol's Opdivo
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
The Bang For Celgene’s Buck: Looking Inside The Record-Setting Juno Deal
Flexus flips IDO inhibitors to Bristol-Myers for up to $1.25bn

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100403

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel